Boston Scientific (BSX)
(Delayed Data from NYSE)
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.59 USD
-1.18 (-1.33%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $87.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Zacks News
Becton Dickinson (BDX) Earnings Surpass Estimates in Q2
by Zacks Equity Research
Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal second quarter.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bruker's (BRKR) robust performances across segments and geographies manage to drive its Q1 sales despite pandemic-led business challenges.
Tandem Diabetes (TNDM) Q1 Net Loss Narrows, Guidance Up
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong international and domestic pump sales and shipment boosted the first-quarter top line.
NuVasive (NUVA) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
NuVasive's (NUVA) first-quarter revenues improved year over year led by progress in U.S. procedural volumes and international business.
Cardinal Health (CAH) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results reflect weakness in Pharmaceutical segment.
Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Cerner's (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Managed services units, and expansion in gross margin.
Allscripts (MDRX) Inches Up 0.3% on Earnings Beat in Q1
by Zacks Equity Research
Allscripts (MDRX) witnesses a year- over- year surge in earnings during Q1.
LabCorp (LH) Base Line Growth Solid, COVID-Related Sales Drop
by Zacks Equity Research
LabCorp's (LH) Walgreens-partnership expands to include new integrated digital experiences.
Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.
Here's How Much You'd Have If You Invested $1000 in Boston Scientific a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Exact Sciences (EXAS) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Exact Sciences' (EXAS) first-quarter 2021 revenues improved year over year led by growth in Precision Oncology, COVID-19 testing and Screening revenues.
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from strong segmental performance.
Globus Medical (GMED) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Globus Medical's (GMED) first-quarter 2021 revenues improved year over year on strength in Enabling Technologies and U.S. Spine.
AmerisourceBergen (ABC) Q2 Earnings Beat, Revenues Miss
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results benefit from segmental growth.
Inogen (INGN) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Inogen (INGN) gains traction from revenue growth within its Rental segment in Q1.
PRA Health (PRAH) Stock Down 0.3% Despite Q1 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the first quarter.
Zimmer Biomet (ZBH) Q1 Earnings Top, Operating Margin Up
by Zacks Equity Research
Zimmer Biomet's (ZBH) core hip and S.E.T. business registers growth in the reported quarter.
Henry Schein (HSIC) Q1 Earnings Top Estimates, '21 EPS View Up
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q1 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.
IDEXX (IDXX) Earnings Beat Estimates in Q1, '21 View Up
by Zacks Equity Research
IDEXX (IDXX) registers strong contribution from its CAG business in the first quarter despite pandemic-induced challenges.
CVS Health (CVS) Q1 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
CVS Health's (CVS) revenues across all the three operating segments improve in Q1. Increased guidance amid the pandemic scenario is another positive.
4 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Stryker, Boston Scientific Corp, Intuitive Surgical and Asensus Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Stryker, Boston Scientific Corp, Intuitive Surgical and Asensus Surgical
QIAGEN (QGEN) Q1 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.
Pacific Biosciences (PACB) Down 10.8% Despite Narrower Q1 Loss
by Zacks Equity Research
Pacific Biosciences' (PACB) revenues grow in both its segments during the first quarter.
Integer Holdings (ITGR) Loses 1.3% Despite Q1 Earnings Beat
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect weak segmental performance.